Anti Estrogen Steroids 99%Min Purity Letrozole female CAS No 112809-51-5

Anti Estrogen Steroids 99%Min Purity Letrozole female CAS No 112809-51-5

Basic Info:

Shipment: EMS, DHL, FedExSpecification: USP/BP
HS Code: 2937290023
Alias: Letrazol-E
Molecular Formula: C17h11n5
Appearance: White Power
Delivery Time: 5-7 Working Days
Payment: & Money Gram
Trademark: nanjianSynonyms: FEMARA;CGS-20267;LETROZOL;LETROZO/LE;Letrozo/leUsp28;Letrozo/le99%;CGS-20267, Femara

Product Description:

 

Femara is a third generation aromatase inhibitor. Like most aromatase inhibitors it was developed to fight breast cancer by inhibiting aromatization via the aromatase enzyme. It is similar to arimidex, however femara is much more potent in it's ability and is used primarily when other treatments such as selective estrogen receptor modulators have failed to produce results. This is why the majority of the research about femara has been conducted on post-menopausal women, but of course some of the findings can be translated over for the benefit of athletes.

Use/Dosing:

Anecdotally users have reported seeing good results using doses ranging from about .25mgs per day to .5mgs per day. However these doses do vary quite widely from user to user, including dosing schedules. Some have reported using the compound every other day or every third day with good results. Also, doses reported have ranged from .25mgs to as much as 2.5mgs per day.

Despite this anecdotal evidence it should be noted that doses as low as 100 micrograms can cause the maximum inhibition of the aromatase enzyme. It is therefore advisable that users experiment with their dosages to find what levels can be maintained for the compound to be fully effective, while minimizing side effects. Of course if a user is trying to treat side effects that have already appeared one may want to err on the side of using too much femara and face those side effects rather than dealing with something like gynocomastia. However, the severity of the condition will likely determine this in most cases.

The maximum dosage that a user would want to use would be 2.5mgs per day. It has been shown in numerous studies that this dosage will eliminate nearly all of the estrogen in the body in nearly all individuals. Any dose that is higher than this would simply be unneeded.

Despite the ability to increase the amount of lutenizing hormone, follicle stimulating hormone, and sex hormone binding globulin in users femara can be counterproductive if used during post-cycle therapy. This is due to the ability of the compound to drive estrogen levels too low during use. Once the compound is discontinued this can result in a "rebound effect" in estrogen levels with these becoming quite high, something that should be avoided during or after post-cycle therapy. Anastrozole could be seen as an alternative to femara in this capacity as it seemingly does not have such a potent effect. The detrimental effect that femara has on blood lipid levels is another reason why many will avoid it's use during post-cycle therapy, and this is discussed below.

 

Detail:

Femara is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.

Femara is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs, like tamoxifen. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.

Femara is used for the treatment of post-menopause breast cancer.
Femara is a powerful Aromatase Inhibitor that was developed to fight breast cancer. For athletes and bodybuilders, it is a drug used to combat the estrogenic side effects of anabolic steroids water-retention, acne and gynocomastia. It will also raise testosterone levels because of the lowered estrogen in the body. Side effects from include a lowered sex drive and continuous use can lead to lowered lipid function and an impaired immune system.

 

Application

Femara is used for primarily treating certain kinds of breast cancer in women past menopause. Femara is an aromatase inhibitor. It works by reducing the total amount of estrogen produced primarily in the body. This helps to starve cancer cells by depriving them of estrogen.

In one male test subject was able to reduce estrogen levels to undetectable levels.is able to raise testosterone in male subjects.

Femara is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking(Nolvadex, Soltamox) for 5 years. It is a non-steroidal aromatase inhibitor (lowers estrogen production). This medication is available in generic form. Common side effects include hot flashes, hair loss, joint/bone/muscle pain, tiredness, unusual sweating, nausea, diarrhea, dizziness, and trouble sleeping.

The recommended dose of Femara is one 2.5 mg tablet administered once a day, without regard to meals. Other drugs may interact with Femara. Tell your doctor all prescription and over-the-counter medications and supplements you use. Femara must not be used during pregnancy. It may harm a fetus. Femara is used mainly in women after menopause. If you have recently gone through menopause, discuss birth control with your doctor. Do not use birth control containing estrogen. It is unknown if this drug passes into breast milk and may harm a nursing infant. Breast-feeding while using this drug is not recommended.

 

Model NO	112809-51-5
CAS No	112809-51-5
Molecular Weight	285.3
Assay	99%Min
Minimum Order Quantity	10 Grams